Adenocarcinoma in situ

Summary

Adenocarcinoma in situ (MONDO:0003218) is a disease and 22 clinical trials. A subtype of in situ carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 22

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	adenocarcinoma in situ
Mondo ID	MONDO:0003218
MeSH	D065311
DOID	DOID:4943
NCIT	C4123
UMLS	C0334276
MedGen	87203
Is cancer (heuristic)	no

Also known as: adenocarcinoma in situ · AIS

Disease family

This is a subtype of in situ carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › in situ carcinoma › adenocarcinoma in situ

Related subtypes (20): oral cavity carcinoma in situ, pharynx carcinoma in situ, gall bladder carcinoma in situ, nasal cavity carcinoma in situ, skin carcinoma in situ, breast carcinoma in situ, eye carcinoma in situ, lung carcinoma in situ, squamous carcinoma in situ, larynx carcinoma in situ, intestine carcinoma in situ, bladder carcinoma in situ, esophagus carcinoma in situ, uterus carcinoma in situ, liver carcinoma in situ, stomach carcinoma in situ, kidney carcinoma in situ, grade III prostatic intraepithelial neoplasia, carcinoma in situ of ureter, carcinoma in situ of urethra

Subtypes (3): lung adenocarcinoma in situ, ductal breast carcinoma in situ, lobular breast carcinoma in situ

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 22.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	12
PHASE3	7
PHASE4	1
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01544478	PHASE4	COMPLETED	V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110)
NCT04422366	PHASE3	RECRUITING	Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
NCT04895020	PHASE3	RECRUITING	Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
NCT07520565	PHASE3	RECRUITING	A Multicentre, Randomised, Double-blind, Placebo-parallel Controlled Phase Ⅲ Clinical Trial Evaluating the Efficacy and Safety of BXOS110 Injection in the Treatment of Acute Ischaemic Stroke Within 3 Hours of Onset.
NCT03546842	PHASE3	COMPLETED	Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)
NCT04425291	PHASE3	COMPLETED	Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
NCT05372016	PHASE3	COMPLETED	Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
NCT05584332	PHASE3	TERMINATED	A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females
NCT02905565	PHASE2	COMPLETED	NBP in Adult Patients With Acute Ischemic Stroke (AIS)
NCT03676101	PHASE1	COMPLETED	Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
NCT04755517	Not specified	ENROLLING_BY_INVITATION	Effectiveness of Cervical Screening in Unvaccinated, Herd Effect Protected Women (HPV400)
NCT05466383	Not specified	RECRUITING	Screening and Intervention for AIS in Haikou, Hainan Province, China
NCT05613283	Not specified	ACTIVE_NOT_RECRUITING	Primary Cervical Cancer Screening by Self-sampling HPV Test
NCT06702657	Not specified	NOT_YET_RECRUITING	A Randomized Clinical Trial on Urgent Angioplasty for IntraCranial Atherosclerotic Stenosis-related Large-Vessel Occlusion After Mechanical Thrombectomy
NCT07194564	Not specified	ACTIVE_NOT_RECRUITING	Acute Training Effect Assessment in Adolescent Idiopathic Scoliosis
NCT02937155	Not specified	UNKNOWN	In the Era of the HPV Vaccine, What Are The Current HPV Subtypes Contributing to High Grade Cervical Dysplasia, Adenocarcinoma in Situ, and Early Cervical Cancer?
NCT03105063	Not specified	UNKNOWN	Evaluation of the AIIS Using Hip Ultrasound(AIISUS)
NCT05152329	Not specified	UNKNOWN	Investigating the Potential Psychological Impact of Early Screening and Long-term Monitoring for Adolescent Idiopathic Scoliosis Among Patients and Caregivers
NCT05210348	Not specified	UNKNOWN	Clinical Evaluation of Detection of High Risk HPV in Urine
NCT05473975	Not specified	COMPLETED	Search for a Recanalization of the Sylvian Artery Electro-Physiological Biomarker
NCT05496361	Not specified	COMPLETED	A Prospective, Multi-center and Randomized Controlled Trial of Tianyi Revascularization Device in Acute Ischemic Stroke
NCT06251505	Not specified	COMPLETED	Cervical Alignment Changes After Correction of Thoracic Adolescent Idiopathic Scoliosis With Thoracic Hypokyphosis